- Home
- MBC vs ORKA Comparison
MBC vs ORKA Comparison
Compare MBC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | ORKA |
|---|---|---|
| Founded | 1954 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MBC | ORKA |
|---|---|---|
| Price | $11.54 | $30.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $15.00 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 1.9M | 412.0K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $2,757,800,000.00 | N/A |
| Revenue This Year | $0.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.50 | ★ N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $9.33 | $5.49 |
| 52 Week High | $18.15 | $32.28 |
Technical Indicators
Market Signals| Indicator | MBC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 55.78 |
| Support Level | $10.88 | $29.38 |
| Resistance Level | $12.02 | $32.28 |
| Average True Range (ATR) | 0.41 | 1.63 |
| MACD | 0.16 | -0.11 |
| Stochastic Oscillator | 72.21 | 62.17 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.